Alternative treatments for Clostridium difficile disease: what really works?
University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu Vancomycin and metronidazole have been used for treating Clostridium difficile- associated disease (CDAD) for the past 25 years, but approximately 20 %...
Gespeichert in:
| Veröffentlicht in: | Journal of medical microbiology 2005-02, Vol.54 (2), p.101-111 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111 |
|---|---|
| container_issue | 2 |
| container_start_page | 101 |
| container_title | Journal of medical microbiology |
| container_volume | 54 |
| creator | McFarland, Lynne V |
| description | University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA
Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu
Vancomycin and metronidazole have been used for treating Clostridium difficile- associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.
This paper was presented at the First International Clostridium difficile Symposium, Kranjska Gora, Slovenia, 57 May 2004. |
| doi_str_mv | 10.1099/jmm.0.45753-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17836853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17836853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-4f370a8acac32910f6d5752bdb90f02043f53e2f653494047d8a119d47d6d673</originalsourceid><addsrcrecordid>eNpFkL1PwzAUxC0EoqUwsqIswJTy_JmEBVUVX1Illu6Wm9jU4CTFdqj473FpJaZ3w-_dnQ6hSwxTDFV199G2U5gyXnCawxEaY1bQnAvGjtEYgJCcCMxH6CyEDwBcUFqdohHmoqAcyBgtZi5q36lov3UWvVax1V0Mmel9Nnd9iN42dmizxhpja-t0UkGroO-z7VrFLH0495Nte_8ZHs7RiVEu6IvDnaDl0-Ny_pIv3p5f57NFXjNCY84MLUCVqlY1JRUGI5pUn6yaVQUGCDBqONXECE5ZxYAVTakwrpokRJOKT9DN3nbj-69BhyhbG2rtnOp0PwSJi5KKktME5nuw9n0IXhu58bZV_kdikLv1ZFpPgvxbT0Lirw7Gw6rVzT99mCsB1wdAhVo541VX2_DPiRJKUe6Cb_fc2r6vt9Zr-a671qYaK9vvQjmTJDXA9BeQ94Wg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17836853</pqid></control><display><type>article</type><title>Alternative treatments for Clostridium difficile disease: what really works?</title><source>MEDLINE</source><source>Microbiology Society</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>McFarland, Lynne V</creator><creatorcontrib>McFarland, Lynne V</creatorcontrib><description>University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA
Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu
Vancomycin and metronidazole have been used for treating Clostridium difficile- associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.
This paper was presented at the First International Clostridium difficile Symposium, Kranjska Gora, Slovenia, 57 May 2004.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.45753-0</identifier><identifier>PMID: 15673502</identifier><identifier>CODEN: JMMIAV</identifier><language>eng</language><publisher>Reading: Soc General Microbiol</publisher><subject>Anti-Infective Agents - therapeutic use ; Biological and medical sciences ; Carrier State - drug therapy ; Clostridium difficile ; Clostridium difficile - isolation & purification ; Clostridium Infections - drug therapy ; Clostridium Infections - epidemiology ; Colitis - microbiology ; Colitis - prevention & control ; Complementary Therapies ; Cross Infection - microbiology ; Cross Infection - prevention & control ; Fundamental and applied biological sciences. Psychology ; Humans ; Infectious diseases ; Medical sciences ; Metronidazole - therapeutic use ; Microbiology ; Vancomycin - therapeutic use</subject><ispartof>Journal of medical microbiology, 2005-02, Vol.54 (2), p.101-111</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-4f370a8acac32910f6d5752bdb90f02043f53e2f653494047d8a119d47d6d673</citedby><cites>FETCH-LOGICAL-c423t-4f370a8acac32910f6d5752bdb90f02043f53e2f653494047d8a119d47d6d673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,3732,3733,23910,23911,25119,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16808683$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15673502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McFarland, Lynne V</creatorcontrib><title>Alternative treatments for Clostridium difficile disease: what really works?</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA
Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu
Vancomycin and metronidazole have been used for treating Clostridium difficile- associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.
This paper was presented at the First International Clostridium difficile Symposium, Kranjska Gora, Slovenia, 57 May 2004.</description><subject>Anti-Infective Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carrier State - drug therapy</subject><subject>Clostridium difficile</subject><subject>Clostridium difficile - isolation & purification</subject><subject>Clostridium Infections - drug therapy</subject><subject>Clostridium Infections - epidemiology</subject><subject>Colitis - microbiology</subject><subject>Colitis - prevention & control</subject><subject>Complementary Therapies</subject><subject>Cross Infection - microbiology</subject><subject>Cross Infection - prevention & control</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Metronidazole - therapeutic use</subject><subject>Microbiology</subject><subject>Vancomycin - therapeutic use</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkL1PwzAUxC0EoqUwsqIswJTy_JmEBVUVX1Illu6Wm9jU4CTFdqj473FpJaZ3w-_dnQ6hSwxTDFV199G2U5gyXnCawxEaY1bQnAvGjtEYgJCcCMxH6CyEDwBcUFqdohHmoqAcyBgtZi5q36lov3UWvVax1V0Mmel9Nnd9iN42dmizxhpja-t0UkGroO-z7VrFLH0495Nte_8ZHs7RiVEu6IvDnaDl0-Ny_pIv3p5f57NFXjNCY84MLUCVqlY1JRUGI5pUn6yaVQUGCDBqONXECE5ZxYAVTakwrpokRJOKT9DN3nbj-69BhyhbG2rtnOp0PwSJi5KKktME5nuw9n0IXhu58bZV_kdikLv1ZFpPgvxbT0Lirw7Gw6rVzT99mCsB1wdAhVo541VX2_DPiRJKUe6Cb_fc2r6vt9Zr-a671qYaK9vvQjmTJDXA9BeQ94Wg</recordid><startdate>20050201</startdate><enddate>20050201</enddate><creator>McFarland, Lynne V</creator><general>Soc General Microbiol</general><general>Society for General Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20050201</creationdate><title>Alternative treatments for Clostridium difficile disease: what really works?</title><author>McFarland, Lynne V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-4f370a8acac32910f6d5752bdb90f02043f53e2f653494047d8a119d47d6d673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carrier State - drug therapy</topic><topic>Clostridium difficile</topic><topic>Clostridium difficile - isolation & purification</topic><topic>Clostridium Infections - drug therapy</topic><topic>Clostridium Infections - epidemiology</topic><topic>Colitis - microbiology</topic><topic>Colitis - prevention & control</topic><topic>Complementary Therapies</topic><topic>Cross Infection - microbiology</topic><topic>Cross Infection - prevention & control</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Metronidazole - therapeutic use</topic><topic>Microbiology</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McFarland, Lynne V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McFarland, Lynne V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alternative treatments for Clostridium difficile disease: what really works?</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2005-02-01</date><risdate>2005</risdate><volume>54</volume><issue>2</issue><spage>101</spage><epage>111</epage><pages>101-111</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><coden>JMMIAV</coden><abstract>University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA
Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu
Vancomycin and metronidazole have been used for treating Clostridium difficile- associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.
This paper was presented at the First International Clostridium difficile Symposium, Kranjska Gora, Slovenia, 57 May 2004.</abstract><cop>Reading</cop><pub>Soc General Microbiol</pub><pmid>15673502</pmid><doi>10.1099/jmm.0.45753-0</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2615 |
| ispartof | Journal of medical microbiology, 2005-02, Vol.54 (2), p.101-111 |
| issn | 0022-2615 1473-5644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17836853 |
| source | MEDLINE; Microbiology Society; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Anti-Infective Agents - therapeutic use Biological and medical sciences Carrier State - drug therapy Clostridium difficile Clostridium difficile - isolation & purification Clostridium Infections - drug therapy Clostridium Infections - epidemiology Colitis - microbiology Colitis - prevention & control Complementary Therapies Cross Infection - microbiology Cross Infection - prevention & control Fundamental and applied biological sciences. Psychology Humans Infectious diseases Medical sciences Metronidazole - therapeutic use Microbiology Vancomycin - therapeutic use |
| title | Alternative treatments for Clostridium difficile disease: what really works? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T18%3A56%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alternative%20treatments%20for%20Clostridium%20difficile%20disease:%20what%20really%20works?&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=McFarland,%20Lynne%20V&rft.date=2005-02-01&rft.volume=54&rft.issue=2&rft.spage=101&rft.epage=111&rft.pages=101-111&rft.issn=0022-2615&rft.eissn=1473-5644&rft.coden=JMMIAV&rft_id=info:doi/10.1099/jmm.0.45753-0&rft_dat=%3Cproquest_cross%3E17836853%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17836853&rft_id=info:pmid/15673502&rfr_iscdi=true |